الفهرس 
IntroductionOnly 14 pages are availabe for public view
 |  | from | 170 |  |  |
| | | from | 170 | | |
Abstract
The COVID-19 pandemic is a public health emergency. Bronchiectasis also presents with pulmonary fibrotic changes presumably secondary to the COVID-19 pneumonia The aim of our study is to estimate the prevalence and pattern of bronchiectasis as atypical COVID-19 presentation and to evaluate the course of COVID-19 infection in bronchiectasis patients A total of 425 patients with confirmed COVID-19 infection were enrolled in the current study. Based on development of bronchiectasis, those patients were subdivided into the following groups group I included COVID-19 patients without bronchiectasis, 400 (94.1%) patientsgroup II included COVID-19 patients who developed bronchiectasis, 14 (3.3%) patientsgroup III included patients with bronchiectasis patients with COVID-19 infection, 11 (2.6%) patients. All patients were subjected to the following: full medical history, examination and investigations including PCR, HRCT and other inflammatory markers. Patients without bronchiectasis had significantly lower frequency of COPD in comparison to those developing bronchiectasis (6.5% vs. 42.9%; p< 0.001) and bronchiectasis with COVID-19 group (6.5% vs. 45.5%; p< 0.001).Patients without bronchiectasis had significantly lower cough score in comparison to those developing bronchiectasis (3.05 ± 1.88 vs. 4.93 ± 0.27; p< 0.001) and bronchiectasis with COVID-19 group (3.05 ± 1.88 vs. 5; p< 0.001). it was found that frequency of colored sputum was significantly lower among those without bronchiectasis (18.8% vs. 72.7%; p< 0.001) and bronchiectasis with COVID-19 group (18.8% vs. 72.7%; p< 0.001). The mMRC score, frequency of respiratory failure and distressed were significantly higher among those de novo and preexisting bronchiectasis with COVID-19 group in comparison to those without bronchiectasis. It was found that serum ferritin was significantly lower among those without bronchiectasis in comparison to those developing bronchiectasis (489.74 ± 222.34 vs. 1392.97 ± 969.32; p< 0.001) and bronchiectasis with COVID-19 group (489.74 ± 222.34 vs. 1312.01 ± 835.44; p< 0.001). Oxygen saturation at admission was significantly higher among those without bronchiectasis in comparison to those developing bronchiectasis (84.38 ± 14.10 vs. 62.29 ± 15.67; p< 0.001) and bronchiectasis with COVID-19 group (84.38 ± 14.10 vs. 70.54 ± 13.82; p< 0.001).